Merck discontinues Bellwave clinical program for blood cancer drug Nemtabrutinib

By: IPP Bureau

Last updated : November 18, 2026 9:23 am



The pharma major is halting the Phase 3 BELLWAVE-011 trial after an external Data Monitoring Committee found that the study's potential benefits may not outweigh its risks


Merck (known as MSD outside North America) has discontinued the BELLWAVE clinical trials for nemtabrutinib (MK-1026). The investigational oral BTK inhibitor was under evaluation for chronic lymphocytic leukemia (CLL), small lymphocytic leukemia (SLL), and other hematologic malignancies.

The pharma major is halting the Phase 3 BELLWAVE-011 trial after an external Data Monitoring Committee found that the study's potential benefits may not outweigh its risks. Following a comprehensive review of all available data, Merck confirmed this assessment and decided to terminate the entire BELLWAVE clinical development program, which includes the Phase 3 BELLWAVE-008 and BELLWAVE-010 studies.

Merck is informing study investigators for these clinical trials and advises patients to speak to their study team and physician regarding next steps and treatment options. Data analyses for these trials are ongoing, and the results will be shared with the scientific community.

“Following careful analyses of the data from BELLWAVE-011, the decision has been made to discontinue development of nemtabrutinib across the entire clinical program. We are grateful to all of the patients, caregivers and investigators for their many contributions that made these studies possible,” said Dr. Marjorie Green, senior vice president and head of global oncology clinical development, Merck Research Laboratories. “We continue to pursue solutions for patients with hematologic malignancies and focus on advancing our hematology pipeline to help more patients with blood cancers.”

Merck Bellwave clinical program blood cancer drug Nemtabrutinib

First Published : November 18, 2026 12:00 am